SFA Therapeutics, Inc. To Present At Bio Investors Forum
Ohio Pen/10032167

PHILADELPHIA - OhioPen -- SFA Therapeutics, Inc. announced today that their CEO, Dr. Ira Spector, will update the company's clinical development plans for several new therapeutic agents they have derived from the human microbiome. The presentation will be delivered as part of the prestigious Bio Investors Forum on October 23rd at 9:45AM in the Elizabethan Room of the Westin St. Francis Hotel in San Francisco, CA.

About SFA Therapeutics

SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML.  SFA currently has five drugs under development, and is targeting psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets.

More on Ohio Pen

• Bahamas Import Assistant Launches Same-Day Pet Permit Service Under BAHFSA's 2024 Expansion
• Liftoff Enterprises Launches Liftoff Spotlight,™ A Nationally Broadcast Platform Turning Conversations Into Revenue
• From November 24th to 27th, Fuqing Invites You to Join Us at BIG 5 to Jointly Build a New Future for Middle Eastern Architecture
• Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
• Stratum Nutrition's OVOLUX™ Named 2025 "Collagen Ingredient of the Year" by Beauty Innovation Awards

SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit www.sfatherapeutics.com to learn more.